Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations. (October 2022) - Ng, P.Y.; Han, Y.C.; Shin Ogawa, L.; Schulz, R.; Yang, S.N.; Jewett, I.; Ishiyama, N.; Romashko, D.; Salomatov, A.; Thakur, S.; Lucas, M.; Lin, T.A.; et al.